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Many human diseases stem from mutations
in an individual's DNA. These diseases may
be inherited diseases such as cystic fibrosis,
diabetes, and muscular dystrophy, or
acquired diseases such as cancer and AIDS.
Researchers in both academic and commer-
cial settings are identifying the genetic basis
ofincreasing numbers ofhuman diseases at a
dizzying pace-a trend that has yielded the
recent discovery ofthe genes linked to adult
leukemia, Huntington's disease, colon can- A
cer, and Lou Gehrig's disease. Such strides d
in genetic research call for tools that can J
help scientists work more efficiently in
their quest to understand the relation-
ship between certain genes and
human disease. One such tool- is a
new technology that enables researchers to
analyze human genes using a microchip, and
it's nowon thewayto themarketplace.
Microchips developed by a team at
Affymetrix in Santa Clara, California, may
some day replace traditional blood tests or
other laboratory diagnostic procedures.
Affymetrix's GeneChip products enable
detection and characterization of large
amounts ofgenetic information, according to
Richard Rava, Affymetrix's vice president for
research andengineering. Theyprovideadra-
matic departure from traditional, more cum-
bersome laboratory analysis methods used to
extract genetic information. The GeneChip
products are developed using a combination
ofphotolithographic techniques common in
the semiconductor industry and chemical
synthesis: huge numbers ofoligonudeotides,
or DNA molecules, are synthesized very
rapidly on the surface of a tiny microchip
approximately onecentimetersquare.
The technology relies on "combinatorial
chemistry, or the synthesis ofmany different
chemicals in a minimum number ofchemi-
cal steps," explains Rava, a physical chemist
with extensive experience in instrumentation
systems and software engineering. "Tens of
thousands ofdifferent oligonucleotides are
synthesized in averysmall area."
This innovation is based i upon Affy-
metrix's very large scale immobilized poly~-
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mer synthesis (VLSIPS) technology.
Introduced in 1991 byAffymetrix Scientific
Director Stephen Fodor and colleagues at
Affymax, parent company to Affymetrix,
VLSIPS allows for the rapid and automated
synthesis oflarge arrays ofchemical entities
on thesurface ofatinymicrochip.
Transforming GeneticResearch
Although the Affymetrix chip technology
was first applied to discovering new drug
therapies, the company recently has worked
to tailor the chip for use in medical research
and dinical diagnostic settings. Researchers
and laboratory technicians will use the
GeneChip system as a standard format for
analyzing large amounts ofgenetic informa-
tion in a single test, boosting cost effective-
ness, speed, and reliability.
According to Paul Berg, professor ofbio-
chemistry and director of Stanford Uni-
versity Medical Center's Beckman Center,
Affymetrix hasjust begun to explore the util-
ity ofthis technology in the research market.
"The commercial market will require-a dif-
ferent capability," says Berg, who received
the 1980 Nobel Prize in Chemistry and
serves on Affymetrix's board of scientific
advisors.
"It's not going to be that inexpensive,"
Berg says of the technology. "We'll maybe
have 25 to 35 machines going to research
I
markets [at first]," he explains. "Ultimately,
as the price goes down, one would expect
that lots ofhospitals could have one in their
laboratory."
Affymetrix and partner Molecular
Dynamics Inc. will be joined by researchers
at the California Institute ofTechnology,
the Lawrence Livermore National Labor-
atory, Stanford University, the University of
California at Berkeley, and the University
ofWashington to develop the next gener-
i ationofDNAdiagnosticdevices.
This team recently received a $31.5
million award under the National
Institute of Standards and Tech-
nology's (NIST) Advanced Tech-
nology Program, which is adminis-
tered by the U.S. Department ofCommerce
AdvancedTechnologyProgram. Members of
the consortium will match that sum dollar
fordollar.
Stan Abramowitz, program manager of
NIST's Advanced Technology Program,
explains why theAffymetrix-led consortium
won one ofthe program's 13 grants set aside
for thosewho are developing DNAdiagnos-
tic tools: "They had an interesting proposal
that would not only develop the chip tech-
nology, but also the [readers], etc. They had
an ambitious, broad-based technology."
Under the grant, the consortium will
develop miniature, integrated devices for a
wide variety of DNA diagnostics.
Affymetrix ultimately envisions a hand-
held device capable ofaccepting a patient
sample, extracting DNA from the sample,
amplifying the target DNA using estab-
lished techniques, and analyzing the
resulting data. Molecular Dynamics will
design the hand-held reader, a product
that maybe severalyears from realization.
Meanwhile, engineers at the Hewlett-
Packard Company are working alongside
Affymetrix to develop and manufacture
scanners that will be marketed in the near
future. Thechip and readersystemwill help
researchers obtain and analyze datagathered
from- the GeneChip arrays. They are
designed to give test results in only two to
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ing tests can take afull dayto complete.
Another collaborator on the DNA
GeneChip products is the Genetics Insti-
tute, a Cambridge, Massachusetts, bio-
pharmaceutical firm engaged in the devel-
opment of drugs through recombinant
DNA and other technologies. Genetics
Institute is providing research funding for
the development of novel assays using
Affymetrix's GeneChip technology. The
company hopes to apply the chip technol-
ogy to their particular area of expertise,
gene expression monitoring. Using the
GeneChip arrays, Genetics Institute scien-
tists can rapidly and simultaneously screen
for the expression of a specified group of
genes in both normal tissue and diseased
cells, thus identifying potentially impor-
tant therapeutic proteins.
Sequence ofProgress
Just as photolithography has transformed
the microelectronics industry, the
microchip has the potential to transform
scientific research. Fodor, Rava, and their
colleagues devised a method in which light
directs the simultaneous synthesis of tens
to hundreds of thousands of different
chemical compounds in precise locations
on a solid support, the microchip.
Affymetrix also developed a complemen-
tary technology that uses laser confocal flu-
orescence scanning to detect molecular
binding events at different points on the
array. Used together, these technologies
make up a miniaturized test format that
promises to transform scientific under-
standing of the molecular basis of human
disease.
Here's how the chip is made: In the
first ofmany cycles, the chip is coated with
a nucleotide linked to a light-sensitive
chemical "block" group that halts subse-
quent reactions. Light is directed through a
photolithographic mask, illuminating spe-
cific grid squares on the chip and causing
photo-deprotection, or the removal of the
block group in those squares. The chip is
then coated with another photo-protected
nucleotide, which reacts with the exposed
squares. The cycle continues: the chip is
exposed to light through the next mask,
which activates new grid sites for reaction
with the subsequent photo-protected
nucleotide. At each step, chemical cou-
pling occurs at the places on the chip that
have been illuminated in the preceding
step.
Using combinatorial masking strate-
gies, scientists can synthesize large numbers
ofcompounds in a small number ofsteps.
With light-directed, spatially addressable
chemical synthesis technology, Affymetrix
can, on a single chip, and in 32 chemical
steps, construct an array ofall 65,536 pos-
sible combinations of eight nucleotides,
with each one in a known location. The
position of sites within the array and the
resulting compounds depend on the pat-
terns of illumination and the sequence of
reactants used.
In addition to the advantage of its
small scale, this method yields another
benefit: "A target molecule can now be
incubated with the array, allowing the
assay to be carried out against all members
simultaneously," Fodor and colleagues
reported in their paper published in Nature
in 1993. Fluorescent labeling of the assay
molecule reveals specific interactions with
individual members ofthe matrix.
After the chemical array is assembled,
the chip is mounted on a thermostatically
regulated flow cell. The fluorescently
tagged target molecules-single-stranded
DNA, for example-are put into a solu-
tion. Probing the solution, the microchip
searches for specific sequences. Bright
fluorescent squares would show sequence
matches, while dim ones would reveal
single-base mismatches. According to
Fodor, the matches could uncover genet-
ic defects, such as the gene linked to cys-
tic fibrosis. Analysis of both matches and
mismatches could also reveal the com-
plete nucleotide sequence in a set of
DNA fragments.
DNA sequencing is one of the more
promising applications of GeneChip tech-
nology. Conventional DNA sequencing
methods are cumbersome and time con-
suming, requiring electrophoretic size sepa-
ration of labeled DNA fragments. In
searching for a tool to rapidly extract and
analyze genetic information, Fodor and
colleagues pioneered a new generation of
gene sequencing technology they term
"sequencing by hybridization," or SBH.
The SBH technique uses a microchip
containing a group of short oligonu-
cleotide probes ofdefined sequence, which
are used to search for complementary
sequences on a longer target strand of
DNA. The target DNA sequence is then
replicated using the hybridization pattern.
In one test, a researcher or clinician could
identify many complementary sites on tar-
get DNA and avoid the hundreds, perhaps
thousands, ofsteps that might be required
using conventional hybridization methods.
Fodor and his associates contend that
this new sequencing technique will speed
scientific investigations into human genet-
ics and diagnostics, pathogen detection,
and DNA molecular recognition. "Current
sequencing methodologies [rely] on com-
plex procedures and require substantial
manual effort," the team reported in
Nature. "Sequencing by hybridization has
the potential for transforming many ofthe
manual efforts into more efficient and
automated formats."
And the technique should prove to be
not only faster, but more accurate as well:
matching hybridization patterns may help
resolve sequencing ambiguities from stan-
dard gel techniques. Because single-base
changes cause multiple changes in the
hybridization pattern, oligonucleotide
arrays could become a powerful tool for
checking the accuracy ofa previously iden-
tified DNA sequence or to scan for
changes within a sequence.
Right ontarget. Fluorescence image of a 256-octanucleotide arrayfollowing hybridization.
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The GeneChip system has the potential to
speed diagnosis and refine treatments for
diseases such as AIDS and cancer. An
enhanced understanding of genetic influ-
ences on the human immunodeficiency
virus-which may dictate how an AIDS
patient responds to a drug therapy, for
example-could transform the way the
doctors use drugs to treat the disease.
"One of the challenges in treating HIV,"
Rava explains, "is the viral genetic diversity
that confers drug resistance. The objective
of a GeneChip analysis of the HIV
genome is to provide a genetic fingerprint
ofviral infection."
To obtain such a fingerprint, a clini-
cian would use a DNA chip encoded with
more than 4,000 probes designed to detect
most known mutations of the viral gene.
The virus is first separated from the pa-
tient's blood sample, then DNA is extract-
ed and split into single strands. The
strands are then broken into fragments and
labeled with fluorescent dye. Probes on the
DNA chip then bind to complementary
sequences among the patient's DNA frag-
ments. Next, a laser scans the chip, illumi-
nating the resulting DNA matches and
allowing researchers to reconstruct the
genetic sequence of the virus and deter-
mine if, for example, it has a mutation
leading to drug resistance.
"Pharmaceutical companies can use
this [technology] in an experimental pro-
gram to develop drugs," Berg explains. It
would serve as a useful research tool to
help them know how to combine drug
compounds, as well as monitor changes
that lead to drug resistance, he says.
Affymetrix is also building a DNA chip
to test for mutations in the p53 gene,
which plays a critical role in many types of
cancer, including breast, lung, and colon
cancer. This chip is targeted to researchers
investigating the relationship between
genetic mutations and the onset ofcancer.
The chips might also be used to monitor
mutations in genes caused by external
environmental agents, Rava says.
Other DNA chips will detect inherited
diseases. One chip under development will
be able to detect many of the 450 muta-
tions linked to cystic fibrosis, a devastating
childhood disease. The system can identify
more mutations in the cystic fibrosis gene
with more reliability than conventional
screening methods.
The Next Generation
Although Affymetrix and partners are cur-
rently making the GeneChip system for
use in most clinical diagnostic fields, they
envision other applications as well-in
forensics, industrial testing, agriculture,
and biomedical research. "The range of
uses is just extraordinary," claims Berg.
"We've hardly scratched the surface ofthe
potential ofthese chips."
GeneChip technology could play an
important role in the emerging field of
genomics, a new field in biomedical
research aimed at clarifying the relation-
ship between genetic sequences and
human physiology. "With genomics," says
Rava, "we make measurements at the
DNA level to make determinations about
the biological state of an organism. We
hope to have a technology that will even-
tually enhance everyone's work in the
genomics field."
"The Human Genome Project is cat-
alyzing a revolution in the understanding
of human disease," says Robert Lipshutz,
director of advanced technology at
Affymetrix. "Cost-effective tools, such as
those we intend to develop under [the
Department of Commerce] grant, are
needed to apply these advances broadly in
the healthcare field."
According to Steve C. Clark, senior
vice president for discovery research at the
Genetics Institute, many of the approxi-
mately 70,000 genes in the human
genome have already been identified, but
the function of most of the genes is
unknown. "Knowing a gene's identity, or
DNA sequence, often contributes little to
understanding its biological function,"
Clark explains. Scientists at the Genetics
Institute hope their research using the
DNA chips will lead to the discovery of
new drugs. "Discerning how a gene is reg-
ulated and what biological role it may play
in disease provides a basis for designing
important new drugs," says Clark.
The emerging DNA chip technology
shows incredible promise, but its creators
see drawbacks as well, mainly in the un-
known factors that lie in the path toward
any new technology. "The biggest draw-
back is that, with any new technology in
development, there are unforeseen chal-
lenges," Rava concedes.
For now, the technology's advantages
seem to vastly outweigh any disadvantages.
Bolstered by that conviction-and the
Department of Commerce grant-the key
players in DNA microchip technology are
now refining techniques for the manufac-
ture of the first GeneChip arrays targeted
to users in the research marketplace.
Affymetrix has come a long way toward
realizing this important application in a
relatively short time: the company first
identified the opportunity to use DNA
chip technology in the areas of research
and diagnostics just 18 months ago, and, if
all goes according to plan, the company
will ship the first chips to laboratories later
this year.
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